Bruxism: methods of application and results of treatment with botulinum neuroprotein (Relatox)

The article substantiates the need for the use of botulinum therapy in the management of bruxism as a movement disorder. We present the technique of injecting a new Russian botulinum neuroprotein Relatox into the masticatory muscles of patients with bruxism. We have the positive clinical effects of botulinum therapy, a decrease in the level of pain on the visual analogue scale, normalization of muscle activity according to the surface electromyography of masticatory muscles, a decrease in number of nocturnal bruxism according to abrasion on the foil surface on Brux Checker are shown

АНАЛИЗ ИЗМЕНЕНИЙ ПОКАЗАТЕЛЕЙ СЫВОРОТОЧНОГО ЦИСТАТИНА С, КРЕАТИНИНА И РЕНАЛЬНОГО ЛИПОКАЛИНА, АССОЦИИРОВАННОГО С ЖЕЛАТИНАЗОЙ НЕЙТРОФИЛОВ, У БОЛЬНЫХ ГЕМОРРАГИЧЕСКОЙ ЛИХОРАДКОЙ С ПОЧЕЧНЫМ СИНДРОМОМ

Introduction. Acute kidney injury is a frequent complication of hemorrhagic fever with renal syndrome. The objective evaluation of аcute kidney injury severity degree is significant in determining the amount of medical actions at hemorrhagic fever with renal syndrome.Objective. Тhe shifts of acute kidney injury biomarkers’ levels (urine neutrophil gelatinase-associated lipocalin, serum cystatin C and serum creatinine) at different periods of hemorrhagic fever with renal syndrome were evaluated.Methods. Depending to hemorrhagic fever with renal syndrome severity the patients were divided into groups with severe (n=16) and moderate form of hemorrhagic fever with renal syndrome (n=10); the control group included 10 healthy individuals. The levels of biomarkers were measured by ELISA.Results. Тhe serum concentration of creatinine and cystatin C – markers of glomerular pathology – increased significantly in hemorrhagic fever with renal syndrome, peaking at oligouric period; while changes of cystatin C were more rapid. Urine neutrophil gelatinase-associated lipocalin level – marker of renal tubular damage – increased 30 to 96 times compared to the control group in fever period of hemorrhagic fever with renal syndrome and gradually decreased thereafter.Conclusion. Тhe use of modern biochemical markers of renal pathology (sCystatin C, urine neutrophil gelatinaseassociated lipocalin) in hemorrhagic fever with renal syndrome, along with traditional indicators, allows a more differentiated approach to the assessment of renal pathology and gives additional evidence to highlight stage and severity of the disease.Введение. Острое повреждение почек является частым осложнением геморрагической лихорадки с почечным синдромом. Объективная оценка степени острого повреждение почек очень важна в определении объема лечебных мероприятий у больных.Цель. Провести анализ изменений концентрации биохимических маркеров острого почечного повреждения (липокалин, ассоциированный с желатиназой нейтрофилов, в моче, цистатин C и креатинин в сыворотке крови) в различные периоды геморрагической лихорадки с почечным синдромом.Методы. Больные были разделены на группы с тяжелой (n=16) и среднетяжелой (n=10) формой геморрагической лихорадки с почечным синдромом; группа контроля состояла из здоровых людей (n=10). Уровень указанных биомаркеров определяли ИФА-методом.Результаты. Концентрация сывороточного креатинина и цистатина С – маркеров гломерулярной патологии – при геморрагической лихорадке с почечным синдромом существенно повышалась, достигая максимума в олигоанурический период; при этом цистатин С проявлял большую динамичность. Концентрация липокалина, ассоциированного с желатиназой нейтрофилов, в моче, отражающая степень повреждения почечных канальцев, уже в лихорадочный период геморрагической лихорадки с почечным синдромом возрастала в 30–96 раз по сравнению с группой контроля, постепенно снижаясь в дальнейшем.Выводы. Использование современных биохимических маркеров почечной патологии при геморрагической лихорадке с почечным синдромом, наряду с традиционными показателями, позволяет более дифференцированно подходить к оценке развития патологии почечных структур, доказательно выделять стадии и судить о степени тяжести заболевания

Бруксизм: методика применения и результаты лечения ботулиническим нейропротеином (Релатокс)

The article substantiates the need for the use of botulinum therapy in the management of bruxism as a movement disorder. We present the technique of injecting a new Russian botulinum neuroprotein Relatox into the masticatory muscles of patients with bruxism. We have the positive clinical effects of botulinum therapy, a decrease in the level of pain on the visual analogue scale, normalization of muscle activity according to the surface electromyography of masticatory muscles, a decrease in number of nocturnal bruxism according to abrasion on the foil surface on Brux Checker are shown.В статье обоснована необходимость применения ботулинотерапии в лечении бруксизма как двигательного расстройства, представлена методика инъекции нового российского препарата ботулинического нейропротеина Релатокс в жевательные мышцы пациентов с бруксизмом. Показаны положительные клинические эффекты ботулинотерапии: снижение уровня боли по визуально-аналоговой шкале боли, нормализация мышечной активности по данным поверхностной электромиографии височных и жевательных мышц, уменьшение проявлений ночного бруксизма по данным площади фасеток стирания на брукс-чекерах

Analyis of changes in the serum concentration of cystatin c, creatinine and renal neutrophil gelatinase-associated lipocalin in patients with hemorrhagic fever with renal syndrome

Introduction. Acute kidney injury is a frequent complication of hemorrhagic fever with renal syndrome. The objective evaluation of аcute kidney injury severity degree is significant in determining the amount of medical actions at hemorrhagic fever with renal syndrome.Objective. Тhe shifts of acute kidney injury biomarkers’ levels (urine neutrophil gelatinase-associated lipocalin, serum cystatin C and serum creatinine) at different periods of hemorrhagic fever with renal syndrome were evaluated.Methods. Depending to hemorrhagic fever with renal syndrome severity the patients were divided into groups with severe (n=16) and moderate form of hemorrhagic fever with renal syndrome (n=10); the control group included 10 healthy individuals. The levels of biomarkers were measured by ELISA.Results. Тhe serum concentration of creatinine and cystatin C – markers of glomerular pathology – increased significantly in hemorrhagic fever with renal syndrome, peaking at oligouric period; while changes of cystatin C were more rapid. Urine neutrophil gelatinase-associated lipocalin level – marker of renal tubular damage – increased 30 to 96 times compared to the control group in fever period of hemorrhagic fever with renal syndrome and gradually decreased thereafter.Conclusion. Тhe use of modern biochemical markers of renal pathology (sCystatin C, urine neutrophil gelatinaseassociated lipocalin) in hemorrhagic fever with renal syndrome, along with traditional indicators, allows a more differentiated approach to the assessment of renal pathology and gives additional evidence to highlight stage and severity of the disease

Phase Equilibrium of Biologically Active Systems 4,6-dinitro-5,7-dichlorobenzofuroxane and 5-nitro-4,6-dichlorobenzofuroxane

Introduction. One of the intensive ways to increase the therapeutic efficacy and safety of a drug is a combination of several already known substances or chemical compounds, leading to the appearance of a synergistic effect. This method of creating a medicinal product is one of the most important trends in recent times, since the synergistic effect allows one to achieve greater pharmacological activity, expand the range of medical applications and reduce the toxic effect of the drug on the organism. These pharmaceutical active substances include a binary mixture "Dimixan"(mixture 4,6-dinitro-5,7-dichlorobenzofuroxan (4,6-DNDHBFO) and 5-nitro-4,6-dichlorobenzofuroxan (5-NDHBFO). They demonstrate potentiated synergism to the ultra-resistant mold fungus of the species Aspergillius niger. However, the synergy mechanism of the mixture of 5-NDHBFO and 4,6-DNDHBFO is not fully studied. The results of determining the thermodynamic characteristics and phase equilibria in these systems will make it possible to determine the nature of the interaction between 5-NDCBPO and 4,6-DNDCBPO, which will undoubtedly contribute to the optimal organization of the production of a promising drug.Aim. Establishing the nature of the interaction between 5-NDHBFO and 4,6-DNDHBFO in the system.Materials and methods. Using differential scanning calorimetry (DSC), phase equilibria in the 5-NDHBFO and 4,6-DNDHBFO systems were studied in a wide range of component concentrations. From the state diagram, the thermodynamic characteristics of the eutectic were determined: the enthalpy and entropy of melting of mixtures of 5-NDHBFO – 4,6-DNDHBFO at different ratios of components.Results and discussion. Based on the results of the study, phase reactions with the physicochemical interaction of 5-NDHBFO and 4,6-DNDHBFO in two-component systems with the formation of eutectic alloys of the "solid solution" type are identified. The specific values of the enthalpies of melting of alloys of eutectic compositions were determined, from which the entropies of melting were calculated. The results of a study of the density of eutectic compositions of 5-NDHBFO – 4,6-DNDHBFO indicate the formation of an interstitial solid solution.Conclusion. The nature of the interaction between 5-NDHBFO and 4,6-DNDHBFO in the system, leading to the appearance of a synergy effect, has been established. The results obtained are important for predicting the eutectic compositions of 5-NDHBFO and 4,6-DNDHBFO as active pharmaceutical ingredient with increased biological activity